NextBiomedical (389650.KQ) Deep Dive: Nexpowder Guards the Downside, Nexphere-F Opens the Upside

Tue, 14 Apr 2026 12:00:00 +0900

Date: 2026-04-14 Close: ~KRW 64,700 | Market Cap: ~KRW 528.3B | 52-Week High/Low: KRW 101,000 / KRW 38,300 Verdict: Wait / Watchlist Core: Nexpowder (commercialized) + Nexphere-F (pipeline) dual structure

TL;DR

NextBiomedical’s current investment thesis is built on a dual structure where Nexpowder supports the downside floor while Nexphere-F opens the upside ceiling.
However, Q1 2026 itself is more of a defensive quarter than an explosive growth quarter. FX effects are limited, and the key question is whether export volumes hold flat and re-accelerate from Q2 onward.
Recent analyst reports are broadly bullish, but the higher the target price, the more additional evidence is needed on Nexphere-F clinical progress, partnership expansion, and cost control.

1. Company Overview & Current Investment Interpretation

NextBiomedical should be evaluated along two business axes.

The first is Nexpowder, an endoscopic hemostatic agent. This product has already entered the commercialization phase across multiple countries including the US, Europe, and Japan, and was the core revenue driver behind most of 2025’s results. It holds FDA 510(k) clearance (K202929), is distributed through Medtronic, is sold in approximately 30 countries, and demonstrated a 94% immediate hemostasis rate in a landmark GUT journal study.

The second is the Nexphere/Nexphere-F absorbable embolization microsphere platform. This axis is not yet at the large-scale revenue stage but is proving its future value through US clinical trials, Japanese regulatory approvals, and global partnerships. It has been granted FDA Breakthrough Device Designation, and first patient enrollment in the RESORB pivotal trial occurred in October 2025.

The current share price simultaneously reflects both axes. Nexpowder supports the earnings floor, while Nexphere-F elevates the valuation multiple. Therefore, this company should not be viewed as a pure earnings play, nor purely as a clinical momentum play. It must be understood as a combination of a product already in commercialization + a pipeline with open-ended value.

2. 2025 Earnings & Cost Structure Review

2.1 Annual Earnings Summary

2025 consolidated revenue: KRW 16.5B
2025 operating loss: KRW 735M
Nexpowder revenue: ~KRW 13.7B

2025 was a year of strong topline growth. However, profitability stopped just short of breakeven. The cause was not COGS but SG&A increases, specifically R&D, clinical trials, and global regulatory preparation costs.

2.2 Cost Structure Analysis

Item	2024	2025	Change
COGS	KRW 3.68B	KRW 4.97B	+35%
SG&A	KRW 9.40B	KRW 12.26B	+30.5%
Gross Margin	61.3%	69.9%	+8.6pp

Two key takeaways:

COGS ratio improved — Gross margin expanded from 61.3% to 69.9%, reflecting better product mix and scale effects.
SG&A grew significantly — Up ~30.5% YoY as the company invested aggressively for the future.

2025 was a year where product economics improved, but the company also spent more aggressively to build its future platform.

2.3 Quarterly Earnings Flow

Q1 2025 Nexpowder revenue: KRW 3.1B
Q2 2025 Nexpowder revenue: KRW 3.4B / Consolidated revenue: KRW 4.0B
Q3 2025 Nexpowder revenue: KRW 4.3B / Consolidated revenue: KRW 4.9B / OP: ~KRW 400M
Q4 2025 Consolidated revenue: KRW 3.8B / OP loss: ~KRW 400M

The interpretation is clear:

Q1-Q3: Stair-step growth
Q3: Breakeven turn triggered market re-rating
Q4: Deceleration and cost impact reconfirmed

2025 confirmed that the growth story is alive, but also that this is still a company with significant quarterly volatility and cost pressure.

3. Hemostatic Agent Export Data & Earnings Correlation

3.1 Export Trends: 2025 vs 2026

Using HS code 3006.10.4000 as a hemostatic export proxy:

2025 Monthly Exports (USD million)

Month	Export Value
Jan	0.85
Feb	0.77
Mar	0.95
Apr	0.80
May	1.14
Jun	0.89
Jul	0.93
Aug	1.04
Sep	1.53
Oct	0.74
Nov	0.98
Dec	0.64

2026 Monthly Exports (USD million)

Month	Export Value
Jan	0.64
Feb	0.95
Mar	1.01
Apr (est.)	1.11

3.2 Quarterly Export-Revenue Correlation

Comparing quarterly exports against Nexpowder revenue reveals remarkably high consistency:

Q1 2025 exports $2.58M → Nexpowder KRW 3.1B
Q2 2025 exports $2.83M → Nexpowder KRW 3.4B
Q3 2025 exports $3.50M → Nexpowder KRW 4.3B
Q4 2025 exports $2.36M → Nexpowder ~KRW 2.9B (implied)

The quarterly conversion factor is nearly constant:

$1M in exports ≈ KRW 1.20~1.23B in Nexpowder revenue

This is highly significant. It means the HS code export data is not just a reference point but a practically useful leading indicator for Nexpowder revenue.

3.3 Q1 2026 Export Interpretation

Q1 2025 exports: ~$2.57-2.58M
Q1 2026 exports: $2.60M

Q1 2026 exports were essentially flat in dollar terms versus a year ago.

The correct reading is not “exports surged” but rather:

January weakness followed by Feb-Mar recovery, with the full quarter roughly defended.

4. FX-Adjusted Q1 2026 Earnings Estimate

4.1 Exchange Rate Comparison

Based on monthly average USD/KRW rates:

Q1 2025 weighted average FX: ~KRW 1,452.98/USD
Q1 2026 weighted average FX: ~KRW 1,465.60/USD

The difference is approximately +0.87%.

A won depreciation effect existed but was sub-1% on a full-quarter basis.

4.2 FX Effect Decomposition

Based on Q1 2025 Nexpowder revenue of KRW 3.1B:

Volume-only Q1 2026 Nexpowder revenue: KRW 3.136B
Volume + FX-adjusted Q1 2026 Nexpowder revenue: KRW 3.163B

The FX contribution was only approximately KRW 27M.

The key to Q1 2026 earnings defense was volume holding flat, not FX tailwinds.

5. Q1 2026 & Full-Year Earnings Estimates

5.1 Q1 2026 Estimate

Based on the export-revenue conversion framework and product mix:

Q1 2026 Nexpowder revenue: ~KRW 3.16B
Q1 2026 consolidated revenue: KRW 3.6~3.8B
Q1 2026 operating income: KRW -200M to breakeven

These numbers are closer to “defended” than “strong.”

5.2 2026 Full-Year Outlook

Base case scenario:

Revenue: KRW 20.5~21.5B
COGS: KRW 6.1~6.4B
SG&A: KRW 14.5~15.5B
Operating income: KRW -200M to +200M

The company will likely remain a near-breakeven business in 2026.

An aggressive scenario of KRW 22.5~23.5B revenue with mid-single-digit billion operating profit is possible, but requires:

Nexpowder growth re-acceleration
Partial deferral or control of Nexphere-F clinical costs

6. Nexpowder (Hemostatic Agent) Progress & Milestones

6.1 Current Stage

Nexpowder is already in the commercialization phase:

US FDA 510(k) clearance (K202929)
2024 indication expansion to lower GI bleeding
Japan PMDA approval and insurance listing completed
September 2025 official Japan launch
Sold in ~30 countries
US distribution through Medtronic
GUT journal landmark study: 94% immediate hemostasis rate

The current bottleneck for Nexpowder is not regulatory approval. The bottleneck is adoption rate.

6.2 Clinical Positioning

The randomized trial published in GUT suggests Nexpowder goes beyond a simple rescue device to demonstrate re-bleeding prevention effects. This differentiates it from competitors including Cook Medical’s Hemospray, EndoClot, and PuraStat.

The real upside for Nexpowder is not being another hemostatic device but rather:

Perception shift toward a standard-of-care adjunctive treatment

6.3 Upcoming Milestones

Post-Japan-launch revenue ramp-up confirmation
US lower GI indication expansion reflected in earnings
Guideline/standard-of-care inclusion

Nexpowder has transitioned from a “regulatory approval story” to an adoption expansion story.

7. Nexphere / Nexphere-F Progress & Milestones

7.1 Current Stage

Nexphere-F’s current status:

Domestic MFDS approval
European CE-MDD
Canadian approval
US FDA IDE approval
FDA Breakthrough Device Designation
FDA Technology Access Pathway (TAP) / CMS Category B progress
RESORB pivotal trial first patient enrolled October 2025 — ~126 patients across 10+ US sites
Japan exclusive distribution deal signed with Asahi Intecc (April 9, 2026)

This product is not yet at the large-scale revenue stage but rather:

Proving value through US clinical trial + Japanese regulatory + global partnerships

7.2 Key Milestones

US RESORB pivotal trial enrollment and progress rate
Japan PMDA regulatory clinical trial initiation
Additional global distribution deals or strategic partnerships
US approval timeline crystallization

The key for this business remains progress rate and probability of success rather than near-term earnings.

Current price: ~KRW 64,700
Market cap: ~KRW 528.3B
52-week high: KRW 101,000
52-week low: ~KRW 38,300

The stock is significantly off its highs but still elevated relative to its lows.

8.2 Price-Earnings Event Correlation

This stock has not reacted mechanically to quarterly numbers alone:

Q3 2025 breakeven turn → Strong re-rating
Q4 2025 deceleration → Numbers were weak but mid-term story partially offset the impact
April 2026 Asahi Intecc deal → +9% single-day move

The stock price function is:

Price = Near-term numbers + Mid-term growth path credibility + Partnership/regulatory momentum

The latter two factors carry more weight.

9. Expected Stock Price Reaction to Q1 2026 Earnings

Base Case

Revenue: KRW 3.6~3.8B
Operating income: KRW -200M to breakeven
Company provides commentary supporting Q2 2026 improvement potential

Expected reaction: Flat to slightly positive (-3% to +5%) — highest probability scenario.

Miss Scenario

Conditions: Revenue below KRW 3.5B, OP loss exceeding KRW -300M, weak Q2 guidance.

Expected reaction: -8% to -15%

Beat Scenario

Conditions: Revenue above KRW 4.0B, operating profit, post-April export improvement + Q2 acceleration commentary.

Expected reaction: +10% to +18%

What will move the stock more at the Q1 2026 earnings release is not the numbers themselves but the credibility of the growth path from Q2 onward.

10. Analyst Report Investment Rationale Analysis

Common Logic

The shared thesis across recent reports can be summarized in one sentence:

Nexpowder supports the earnings floor while Nexphere-F opens the upside through partnerships and clinical trials.

Analyst consensus is Strong Buy with an average target of KRW 97,667.

Broker-by-Broker Differences

Broker	Target	Character
LS Securities	KRW 83,000	Conservative. Execution-value focused.
DB Financial	KRW 90,000	Nexphere-F discount rate lowered by Japan deal.
Daol Investment	KRW 120,000	Nexphere-F at full value via partnerships. Aggressive.
Korea Investment	—	2026 revenue KRW 26B, OP KRW 3B annual breakeven scenario.

Key Debate

The real difference between reports is not “is this a good company?” but rather:

Cost recognition timing and Nexphere-F value discount rate

The divergence comes from:

Who assigns higher clinical success probability
Who sees more partnership upside
Who expects lower cost growth

11. Target Price Reverse Engineering: KRW 83K / 90K / 120K

Based on ~8.204M shares outstanding, implied market caps by target price:

KRW 83,000 → KRW 680.9B (+28.9% upside)
KRW 90,000 → KRW 738.4B (+39.8% upside)
KRW 120,000 → KRW 984.5B (+86.3% upside)

Current market cap at KRW 64,700 is approximately KRW 528.3B.

KRW 83,000

Explainable through Nexpowder earnings defense + conservative Nexphere-F valuation. This is an execution-confirmation target.

KRW 90,000

Reflects Nexphere-F discount rate partially reduced by the Japan partnership. Still grounded in identifiable catalysts.

KRW 120,000

Requires treating Nexphere-F not as an “option” but as “core value.” Four conditions must largely align:

US clinical trial on track
Japan regulatory execution
Additional partnerships
Earnings breakeven trajectory

KRW 83K-90K are execution-confirmation targets; KRW 120K is an expectation-front-loading target.

12. Conclusion

Key Takeaways

NextBiomedical has a genuinely interesting dual structure:

Nexpowder is already commercialized, supporting the earnings floor.
Nexphere-F is opening the multiple ceiling through US/Japan/global partnerships.

The three most important questions right now:

Does Nexpowder actually re-accelerate growth in 2026?
Does the Nexphere-F US clinical trial stay on schedule?
Can revenue growth offset rising costs?

Current assessment:

Q1 2026 is a defensive quarter — not a breakout.
Q2 2026 onward is what matters more.
Nexphere-F value reflection is possible, but the higher the target, the less evidence currently supports it.

Investment Verdict

Wait / Watchlist

This is clearly a quality company. But for the stock to meaningfully re-rate from here, it needs not more expectations but execution evidence — clinical trial progress, partnership monetization, and cost discipline.

Monitoring Checklist

Q1 2026 earnings release (expected mid-May)
- Revenue KRW 3.6~3.8B range
- Operating income KRW -200M to breakeven range
April confirmed exports and May export trends
- Key to judging Q2 2026 re-acceleration
Nexphere-F US RESORB trial progress
- Enrollment pace, site expansion, official updates
Asahi Intecc Japan regulatory trial initiation timeline
- Whether the deal moves to execution phase
Cost structure monitoring
- R&D spend, clinical trial costs, commission fee growth
Nexpowder guideline/standard-of-care developments
- The single largest structural long-term value driver

NextBiomedical is an attractive MedTech company where Nexpowder guards the downside and Nexphere-F opens the upside, but to justify the stock moving meaningfully higher from here, what’s needed is not more expectations but execution evidence — clinical progress, partnership monetization, and cost control.

Embolization Microsphere on Korea Invest Insights